Nordicus Partners Corporation (NORD) Fair Value & Analysis
Industrials · US · Market cap $47.2M
Fair value as of: Jun 25, 2026
Analysis
Nordicus Partners Corporation (NORD) currently trades at $1.63, while our model-based Fair Value estimate is $2.12 — implying the stock looks roughly 30.1% undervalued today. We read business quality at 95/100 (high quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Nordicus Partners Corporation operates as publicly traded business accelerator and holding company for Nordic life sciences companies in the United States. The company focused on developing medicines supporting oral health. It also provides corporate finance activities, including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Nordicus Partners Corporation (NORD) undervalued?
What is the fair value of NORD?
What is the quality score of NORD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.